Immunocore (NASDAQ:IMCR) Downgraded to Neutral Rating by Mizuho

Mizuho cut shares of Immunocore (NASDAQ:IMCR) from an outperform rating to a neutral rating in a research note published on Monday, MarketBeat.com reports. They currently have $38.00 price objective on the stock, down from their prior price objective of $72.00.

Several other equities research analysts have also weighed in on IMCR. UBS Group initiated coverage on Immunocore in a research note on Thursday, October 24th. They issued a “sell” rating and a $24.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. Needham & Company LLC reduced their target price on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Oppenheimer reiterated an “outperform” rating and set a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Finally, Morgan Stanley reduced their price target on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Immunocore currently has an average rating of “Moderate Buy” and a consensus target price of $69.18.

Immunocore Stock Down 0.1 %

IMCR opened at $34.64 on Monday. The company has a market capitalization of $1.73 billion, a P/E ratio of -36.46 and a beta of 0.72. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 5.15. The firm’s fifty day moving average price is $32.61 and its two-hundred day moving average price is $39.09. Immunocore has a fifty-two week low of $29.72 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same period in the previous year, the business earned ($0.59) EPS. The firm’s revenue was up 23.7% on a year-over-year basis. On average, analysts anticipate that Immunocore will post -1.11 EPS for the current year.

Institutional Investors Weigh In On Immunocore

Institutional investors and hedge funds have recently made changes to their positions in the company. Primecap Management Co. CA grew its holdings in Immunocore by 3,841.6% during the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company’s stock worth $66,122,000 after acquiring an additional 1,901,570 shares during the period. Armistice Capital LLC grew its stake in shares of Immunocore by 495.1% during the second quarter. Armistice Capital LLC now owns 976,000 shares of the company’s stock worth $33,077,000 after purchasing an additional 812,000 shares during the period. Millennium Management LLC increased its holdings in Immunocore by 124.4% in the second quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock valued at $20,366,000 after purchasing an additional 333,167 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Immunocore by 86.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company’s stock valued at $22,230,000 after buying an additional 158,455 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Immunocore by 1,867.3% during the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock worth $5,435,000 after buying an additional 152,207 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.